Condition: Pancreatic Cancer · Sponsor: Jinling Hospital, China
The purpose of this study is to evaluate the safety and efficacy of treating pancreatic cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized cancer mRNA vaccines.
This description comes directly from the study's public registry record.
Xinbo Wang, MD · 13505172912 · wxinbo2008@163.com
Sizhen Wang, MD · 15195900565 · wsizhen@163.com
Always discuss trial participation with your own doctor first.
| Wang Sizhen | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06326736